Intermittent hormonal therapy shows similar outcome than SOC in ER+ breast cancer preclinical model.
Pedro M. Enriquez-Navas, Libia Garcia, Mahmoud Abdalah, Olya Stringfield, Kimberly Luddy, Sabrina Hassan, Robert J. Gillies, Robert A. Gatenby.
This study shows intermittent hormonal therapy achieves similar tumor control as standard-of-care in ER+ breast cancer models with reduced drug use and preserved sensitive cell phenotypes.
bioRxiv · Jan 8, 2019 · PreprintCancer Biology